Biotech News

Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results

Annovis Bio (ANVS)Annovis BioEarnings

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational oral therapy for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and reported financial results for the third quarter ended September 30, 2026.

Related news

Annovis Bio

Phase 3 Neurodegenerative Disease Company Annovis Bio is developing buntanetap, an oral candidate for Alzheimer’s disease and Parkinson’s disease. Through an RNA-targeting mechanism, buntanetap is designed to reduce translation of multiple neurotoxic proteins, including APP/amyloid beta, tau, alpha-synuclein, and TDP-43. Registrational...

Recent company news

Stock data

Close
0.75 USD
Market cap
79.13M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States